Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.56 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.56 |
| ▸ | RELA | Q04206 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.52 |
| ▸ | ACP1 | P24666 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770662 | 0.82 | RAB9A (0.45) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL17844701 | 0.79 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL19974134 | 0.79 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL19974151 | 0.79 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL32690316 | 0.79 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL7829112 | 0.79 | — | — | |
| SCHEMBL2451258 | 0.79 | — | — | |
| SCHEMBL8555873 | 0.78 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL30271553 | 0.77 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL19981472 | 0.77 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF PHARMACEUTICALS SA (CH) | 2021-07-22 | — | — | US | disclosed |
| CN-105385011-B | A kind of TPV compositions and automobile collision preventing billot | 嘉兴市博尔塑胶有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-3303283-A1 | FTO INHIBITORS | National Institute Of Biological Sciences, Beijing (CN) | 2018-04-11 | — | — | EP | disclosed |
| CN-105315224-B | Cyclopentylacrylic acid amide derivative | 杏林制药株式会社 | 2018-04-10 | — | — | CN | disclosed |
| WO-2016206573-A1 | FTO INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-12-29 | — | — | WO | disclosed |
| CN-102089291-B | Cyclopentyl acrylamide derivative | 杏林制药株式会社 | 2016-08-17 | — | — | CN | disclosed |
| CN-1809561-B | Phenylacetamides and their use as glucokinase modulators | PROSIDION LTD | 2012-01-25 | — | — | CN | disclosed |
| US-20090036393-A1 | Vesicular monoamine transporter gene therapy in Parkinson's disease | THE UNIVERSITY OF CHICAGO (US) | 2009-02-05 | — | — | US | disclosed |
| US-7115258-B2 | Vesicular monoamine transporter gene therapy in parkinson's disease | ARCH DEVELOPMENT CORP. (US) | 2006-10-03 | — | — | US | disclosed |
| CN-1809561-A | Phenylacetamides and their use as glucokinase modulators | PROSIDION LTD (GB) | 2006-07-26 | — | — | CN | disclosed |
| CN-1185219-C | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2005-01-19 | — | — | CN | disclosed |
| CN-1466584-A | Tetrazolyl-phenyl acetamide glucokinase activators | - | 2004-01-07 | — | — | CN | disclosed |
| US-20030143702-A1 | Vesicular monoamine transporter gene therapy in parkinson's disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-07-31 | — | — | US | disclosed |
| CN-1411453-A | Trans olefinic glucokinase activators | HOFFMANN LA ROCHE (CH) | 2003-04-16 | — | — | CN | disclosed |
| US-6506378-B1 | Increasing efficiency of 3,4-dihydroxyphenylalanine conver-sion to dopamine; sequestering for sustained release; gene transfer modification of donor cells for grafting into central nervous system | ARCH DEVELOPMENT CORPORATION | 2003-01-14 | — | — | US | disclosed |
| US-5712270-A | TREATING PARKINSON*S DISEASE, DOWN*S SYNDROME, AND ALZHEIMER*S DISEASE WITH COGNITION ACTIVATORS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-27 | — | — | US | disclosed |
| US-5510478-A | TREATMENT OF NEUROLOGICAL ILLNESSES RELATED TO CHOLINERGIC DEFICIENCY; ALZHEIMERS'S DISEASE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210221778-A1 | Inhibitors of heat shock factors and uses thereof | HSF1, HSP90AB2P, HSP90AB1 | RAB9A 4035/4885NPC1 3462/4885SMN1; SMN2 4284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.